PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain
- Conditions
- Moderate-severe Pain
- Interventions
- Drug: ALO-02
- First Posted Date
- 2016-02-12
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT02680847
- Locations
- 🇺🇸
Leo Jenkins Cancer Center Pharmacy, Greenville, North Carolina, United States
🇺🇸Children's Hospital Of Los Angeles - University Of Southern California School Of Medicine, Los Angeles, California, United States
🇺🇸University of Illinois Hospital at the Medical Center, Chicago, Illinois, United States
Ameparomo Capsules 250 mg Drug Use Investigation
- Conditions
- Intestinal Amebiasis
- First Posted Date
- 2016-02-11
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT02680665
Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer
- First Posted Date
- 2016-02-10
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 252
- Registration Number
- NCT02679755
- Locations
- 🇮🇳
HealthCare Global Enterprises Ltd., Bangalore, Karnataka, India
🇮🇳Tata Memorial Centre, Tata Memorial Hospital, Mumbai, Maharashtra, India
🇮🇳Shatabdi Hospital, Nashik, Maharashtra, India
Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)
- First Posted Date
- 2016-02-10
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 692
- Registration Number
- NCT02679170
- Locations
- 🇪🇸
Hospital Marqués de Valdecilla, Santander, Cantabria, Spain
🇪🇸Hospital Virgen de los Lirios, Alcoi, Alicante, Spain
🇪🇸Hospital Universitario de La Princesa, Madrid, Spain
Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement
- Conditions
- Osteoarthritis
- Interventions
- Drug: Investigational Medical Product (IMP) administered in parent study
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 154
- Registration Number
- NCT02674386
- Locations
- 🇺🇸
George Stanley Walker, MD, New Orleans, Louisiana, United States
🇭🇺Tolna Megyei Balassa Janos Korhaz, Ortopediai Osztaly, Szekszard, Hungary
🇯🇵Nakajo Orthopedic Clinic, Sendai, Miyagi, Japan
Vfend Special Investigation For Prophylaxis
- Conditions
- Fungal Infection
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 241
- Registration Number
- NCT02674685
Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase
- Conditions
- HypercholesterolemiaHealthy
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2016-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT02667223
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
- Conditions
- Hematologic MalignanciesSolid Tumor
- Interventions
- Drug: PF-07901800 (TTI-621) plus NivolumabDrug: PF-0791800 (TTI-621)Drug: PF-07901800 (TTI-621) plus Rituximab
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 249
- Registration Number
- NCT02663518
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Texas MD Anderson Cancer Center, Melanoma and Skin Clinic, Houston, Texas, United States
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
- First Posted Date
- 2016-01-20
- Last Posted Date
- 2020-05-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 28
- Registration Number
- NCT02659631
- Locations
- 🇺🇸
Huntsman Cancer Hospital, Salt Lake City, Utah, United States
🇺🇸Memorial Sloan Kettering Cancer Center Rockefeller Outpatient Pavillion, New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center- Clinical Trials Office, New York, New York, United States
Determine the PK and Safety and Tolerability of ATM-AVI for the Treatment of cIAIs in Hospitalized Adults (REJUVENATE)
- Conditions
- Complicated Intra-Abdominal Infections, cIAIs
- Interventions
- First Posted Date
- 2016-01-14
- Last Posted Date
- 2020-04-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT02655419
- Locations
- 🇫🇷
CHU Limoges, Limoges cedex, France
🇫🇷University Hospital C., Lille Cedex, France
🇪🇸Hospital Universitario Son Espases, Palma de Mallorca, ISLA Baleares, Spain